September 23, 2009 10:23 ET

Intriguing Revelations: Deciphering CEL-SCI's H1N1 Flu Play

LOS ANGELES, CA--(Marketwire - September 23, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published a new report about CEL-SCI Corporation's (NYSE Amex: CVM) new H1N1 flu drug candidate.

Hype versus substance. Perception versus reality. During the past week, there has been much debate regarding the work being done by CEL-SCI in the pandemic influenza space, but previously published data may help shed new light on the L.E.A.P.S platform which is being used to develop the treatment.

Are there applications for CEL-SCI's work beyond the scope and urgency of the current pandemic that may open up other lucrative markets?

The new article can be read in their entirety at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

For more biomedical sector and investment news go to

Contact Information

  • Mike Havrilla
    Managing Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556